Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

The new quantum computing algorithm, called "Quantum Echoes," is the first that can be independently verified by running it on another quantum computer. When you purchase through links on our site, we ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Dr. McBain studies policies and technologies that serve vulnerable populations. On any given night, countless teenagers confide in artificial intelligence chatbots — sharing their loneliness, anxiety ...

Kara Alaimo is an associate professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was ...

Every time a new slang word gets coined on the Internet, linguist Adam Aleksic is thrilled. “It’s definitely good for me in that I stay in business,” says Aleksic, who studies the origins of words and ...

You’re at the checkout screen after an online shopping spree, ready to enter your credit card number. You type it in and instantly see a red error message ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...